From: Dental implants in patients treated with antiresorptive medication – a systematic literature review
Topic | Identified (n) | Included (n) |
---|---|---|
Outcome osteonecrosis risk. ST (bisphosphonate OR denosumab) AND osteonecrosis jaw AND | ||
Dental implant OR periimplantitis | 105 | 18 |
Denture | 49 | 12 |
Jaw augmentation OR sinus lift | 7 | 0 |
Antibiotics AND dental implant | 16 | 0 |
Xerostomia | 4 | 0 |
CTX | 35 | 0 |
Medication time | 16 | 0 |
Outcome mastification. ST | ||
Masticatory efficiency AND dental implant | 61 | 0 |
TMJ disorder AND dental implant AND prevention | 10 | 0 |
Outcome quality of life. ST (bisphosphonate OR denosumab) AND | ||
Quality of life AND dental implant | 5 | 1 |
Oral health related quality of life AND dental implant | 1 | 0 |
Outcome prognosis remaining dentition. ST (bisphosphonate OR denosumab) AND | ||
Prognosis remaining dentition AND dental implant | 0 | 0 |
Outcome prognosis future implants. ST (bisphosphonate OR denosumab) AND | ||
Dental implant AND prognosis | 16 | 0 |
Persisting alveolar socket | 2 | 2 |
Sharp bone edges AND jaw NOT children NOT osteogenesis imperfecta | 2 | 0 |
Ossification AND jaw NOT children NOT osteogenesis imperfecta | 66 | 0 |
Bone remodeling AND post extraction AND jaw NOT children NOT osteogenesis imperfecta | 7 | |
Radiologic changes AND jaw NOT children NOT ostegenesis imperfect AND dental implant | 1 | 0 |
Hand search | 17 | |
Total | 403 | 50 |